Navigation Links
China Sky One Medical, Inc. Interviewed in The China Perspective
Date:12/5/2008

HARBIN, China, Dec. 5 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical took part in an insightful interview in today's issue of The China Perspective.

As a well-known pharmaceutical company in China, China Sky One was honored to receive an interview from The China Perspective, a leading source of China business news, research and analysis that provides insight into the trends, companies and industries that are shaping the Chinese economy. During the interview, Mr. Yan-Qing Liu spoke about the Company's recent acquisitions, its R&D capability and the impact of global financial crisis on pharmaceutical producers. For more information, please visit The China Perspective's website ( http://www.thechinaperspective.com ).

"This is an exciting time in the evolution of the pharmaceutical industry in China, and China Sky One is well positioned to offer insight as a leading drug manufacturer and distributor in China," commented Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We are thrilled to work with The China Perspective and to share our reflections about the global economic crisis and our expertise in the Chinese pharmaceutical market with the investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR''), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yubo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web site:http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 /PRNewswire/ - The University of Missouri ... a business of Sterigenics International, and General Atomics (GA), ... submitted to the U.S. Nuclear Regulatory Commission (NRC). This ... of molybdenum-99 (Mo-99). Once operational, production from this facility ... demand for Mo-99, which currently must be imported from ...
(Date:3/29/2017)... The Global Microfluidic Chips Market by Manufacturers, ... and comprehensive study on the existing state of the global Microfluidic ... Europe and Asia-Pacific , ... and Africa . ... Browse 172 Tables and Figures, 13 Major Company ...
(Date:3/28/2017)... ... , ... Mass spectrometry is becoming more widely for clinical testing and evaluation ... potential to perform challenging analyses in complex matrices and sample types. While mass spectrometry ... it to be routinely used for medical testing. , In this webinar, ...
(Date:3/28/2017)... Ann Arbor, Michigan (PRWEB) , ... March 28, ... ... company was awarded a Phase II Small Business Innovation Research (SBIR) grant from ... will receive approximately $750,000 over two years to develop a suite of BioGel™ ...
Breaking Biology Technology:
(Date:2/26/2017)...  Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring, announces the appointment of ... "Too often, too many offenders return to jail ... trying to tackle this ongoing problem and improve ... members. While significant steps are underway, Securus continues to ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
(Date:2/13/2017)... WASHINGTON , Feb. 13, 2017 Former ... U.S. Senate Judiciary Committee, Janice Kephart of ... regarding President Donald Trump,s "Executive Order: Protecting ... States" (Jan. 27, 2017):  "As President Trump,s ... 9th Circuit has now essentially banned the travel ban, ...
Breaking Biology News(10 mins):